Drug intelligence / Profile preview

tyrphostin AG 879

Development stage
Preclinical
Lead developer
Hebrew University of Jerusalem
Modality
Small Molecules
01

Overview

Tyrphostin AG 879 is a small molecule tyrosine kinase inhibitor primarily utilized as a research tool for investigating cell signaling pathways. It was originally identified as a selective inhibitor of the **ErbB-2 (HER2)** and **TrkA (NTRK1)** receptor tyrosine kinases. Subsequent studies have expanded its pharmacological profile, demonstrating its ability to inhibit **NTRK3 (TrkC)** and act as an antagonist of the **Wnt/β-catenin** signaling pathway. Beyond direct kinase inhibition, AG 879 has been shown to suppress the expression of the *RAF-1* and *HER-2* genes and significantly inhibit the biosynthesis of phospholipids and fatty acids in animal cells. These diverse mechanisms contribute to its observed antitumoral and antiviral effects in various experimental models, including breast cancer and viral replication assays.

Other names
Tyrphostin 879Tyrphostin879Tyrphostin-879(E)-3-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-cyano-N-(2-phenylethyl)-2-propenamide
02

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)NTRK1 (Tropomyosin-related receptor kinase A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on tyrphostin AG 879.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tyrphostin AG 879.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call